Sentence examples for been described to block from inspiring English sources
L-alanine has been shown to promote germination of multiple bacterial spores [16], [17], [27], [28], while D-alanine has been described to block germination [29].
Thapsigargin has also been described to block the TRPV1 vanilloid receptor 30.
The STAT3 inhibitor Stattic has been described to block the phosphorylation of STAT3 at Tyr705, and we confirmed this result in isolated mitochondria.
Furthermore, caspase-8 inhibition with 50 μM of the peptidic caspase inhibitors zVAD-FMK or IETD-FMK has been described to block IL-2 release from activated T-cells [ 47].
Although ion channels are not the primary targets of imipramine or astemizole, both drugs block different channels with relatively high affinity by binding to intracellular regions; astemizole has been described to block several K+ channels related to Kv10.1, and imipramine blocks Na+, K+ and Ca2+ channels in different preparations [ 25].
Ddit3 heterodimerizes with C/ebp family members to form complexes that cannot bind DNA, thus blocking activation of C/ebp-driven programs, a mechanism that has been described to block differentiation in mesenchymal lineages (Han et al., 2013; Shirakawa et al., 2006).
Interfering with the phospholipid Kennedy's pathway is described to block phospholipid synthesis and to induce apoptosis [30], [49], [50].
Such ONs targeting adjacent sites on both DNA-strands were described to block both RNA polymerase II and III, and were also demonstrated to impair binding of the CCCTC-binding factor CTCF, involved in long-range DNA interactions.
Similarly, overexpression of Bcl-2 and Bcl-XL in NB cell lines was described to block chemotherapy-induced apoptosis, thus suggesting that the expression of these proteins may promote the drug resistance characteristic of high-risk NBs (Dole et al, 1994, 1995).
Of note, memantine blocked synaptic activation although it has been described to preferentially block extrasynaptic over synaptic activity at the used concentration.
The proteasome inhibitor bortezomib has not only been described to inhibit osteolysis by blocking RANKL-mediated bone resorption by osteoclasts [2] but also to stimulate BF.
